150 related articles for article (PubMed ID: 38294126)
21. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
22. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
23. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
Talati C; Sallman D; List AF
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):629-635. PubMed ID: 30097406
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
25. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
26. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
27. Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Sakai H; Miura I; Arai A
J Clin Exp Hematop; 2022 Sep; 62(3):158-163. PubMed ID: 35732408
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
29. [MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes].
Wilk CM; Goede JS
Ther Umsch; 2022; 79(2):87-91. PubMed ID: 35291851
[TBL] [Abstract][Full Text] [Related]
30. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
32. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Giagounidis AA; Germing U; Aul C
Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
[TBL] [Abstract][Full Text] [Related]
33. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
List A; Ebert BL; Fenaux P
Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
[TBL] [Abstract][Full Text] [Related]
34. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
35. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
Drusbosky LM; Cogle CR
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397113
[TBL] [Abstract][Full Text] [Related]
36. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS; List AF
Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
[TBL] [Abstract][Full Text] [Related]
37. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
40. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
